The purpose of the Quatro Study, sponsored by CONRAD is to assess the acceptability, preferences, user experience, and effect on sexual behavior of four different vaginal microbicide or multipurpose technology  (combining HIV and pregnancy prevention) delivery forms, using placebo products in 18- to 30-year-old African women: rapidly disintegrating vaginal insert, intravaginal ring (IVR), film, and gel. The study also examines adherence to the dosage forms through objective markers, developed for each dosage form prior to the commencement of the study. Furthermore, the study assesses acceptability, preferences, and potential barriers to uptake by conducting qualitative interviews and focus group discussions with male partners of women who used the Quatro products and health providers and key stakeholders. RTI International's role is to oversee the study activities, develop research instruments, manage funding, handle logistical issues, and lead analysis and publication. Additionally, the fieldwork is implemented by RTI’s collaborating clinical research sites in Harare, Zimbabwe, and Durban, South Africa. Information gathered in the Quatro Study will lay the foundation for improved, female-initiated HIV-prevention and multipurpose technology products and provide early assessment to modify products, packages, and messages with the goal of increasing product uptake and use.